非酒精性脂肪性肝病合并糖尿病的综合管理:2024年美国糖尿病学会指南解读  

Interpretation of the 2024 American Diabetes Association guidelines for the comprehensive management of non-alcoholic fatty liver disease combined with diabetes mellitus

作　　者：倪文婧 李婕[1,2] 南月敏 Ni Wenjing;Li Jie;Nan Yuemin(Department of Infectious Diseases,Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,Nanjng 210008,China;Department of Infectious Diseases,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210008,China;Department of Traditional and Western Medical Hepatology,Hebei Medical University Third Hospital,the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases,Hebei Province,Hebei International Science and Technology Cooperation Base--Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer,Shijiazhuang 050051,China)

机构地区：[1]南京中医药大学鼓楼临床医学院感染性疾病科,南京210008 [2]南京大学医学院附属鼓楼医院感染性疾病科,南京210008 [3]河北医科大学第三医院中西医结合肝病科,河北省慢性肝病肝纤维化研究重点实验室,河北省国际科技合作基地——河北省肝癌分子诊断国际联合研究中心,石家庄050051

出　　处：《中华肝脏病杂志》2024年第6期504-507,共4页Chinese Journal of Hepatology

基　　金：国家自然科学基金(82170609、81970504)。

摘　　要：非酒精性脂肪性肝病(NAFLD)为成人2型糖尿病(T2DM)及糖尿病前期常见伴发疾病,T2DM/NAFLD患者为心血管疾病的高危人群,NAFLD及其相关肝纤维化的发生和发展、心血管疾病及其相关死亡严重影响患者预后。2024年美国糖尿病学会《糖尿病标准化管理指南》针对T2DM及糖尿病前期人群NAFLD,以及肝纤维化的筛查、评估、治疗及管理提出相关建议。在改善生活方式基础上,减重、控制血糖是减缓肝脏炎症及肝纤维化进展、降低心血管疾病风险的重要措施。Non-alcoholic fatty liver disease(NAFLD)is a common concomitant disease in adults with type 2 diabetes mellitus(T2DM)and prediabetes.Therefore,T2DM/NAFLD patient populations are at high risk for cardiovascular disease.The occurrence and progression of non-alcoholic fatty liver disease-related liver fibrosis and cardiovascular disease have a severe impact on the patient’s prognosis and mortality rate.The American Diabetes Association's 2024"Guidelines for the Standardized Management of Diabetes"put forward recommendations relevant to the screening,evaluation,treatment,and management of NAFLD in T2DM and prediabetic populations,as well as liver fibrosis.The important measures for decelerating liver inflammation and fibrosis progression and the risk of cardiovascular disease are based on improvements in lifestyle methods,weight loss,and blood sugar control.

关 键 词：非酒精性脂肪性肝病 2型糖尿病 心脏代谢风险因素 综合管理 诊断 治疗 

分 类 号：R575.5[医药卫生—消化系统] R587.1[医药卫生—内科学]